A major UK Biobank cohort study involving over 417,000 adults has revealed that clonal hematopoiesis of indeterminate potential (CHIP) is a significant, independent predictor of incident heart failure. Notably, non-DNMT3A CHIP mutations—including TET2, ASXL1, JAK2, and spliceosome gene variants—showed a substantially stronger association with heart failure risk than DNMT3A mutations. While CHIP-related comorbidities such as CAD, atrial fibrillation, type 2 diabetes, and chronic kidney disease contributed to this risk, they mediated only 28% of the association, indicating a primarily direct pathophysiological link.
These findings position CHIP as a novel genomic risk factor, with potential implications for future screening, risk stratification, and targeted heart failure prevention strategies. This study underscores a paradigm shift in how hematologic aging influences cardiovascular…
